Should you build or buy Digital Validation for Life Sciences?
Digital validation software runs the lifecycle for qualifying computer systems in regulated life sciences settings: risk assessment, test scripting, execution, electronic signature and audit-ready summary reports under GAMP 5, FDA CSA guidance and Part 11. Validation, quality and IT teams at pharma, biotech and medtech companies use it before any regulated system can go live.
Buy a validation lifecycle platform when the program spans sites and systems and needs repeatable electronic execution with Part 11 signatures. Extend Jira and Xray only if your teams already work there, the scope is manageable, and you will own the signature integration, configuration validation and ongoing assurance. Treat vendor validation packages as inputs to your own risk-based assurance, not as regulator acceptance.
Build it, buy it, or bridge?
When building makes sense
Regulated teams do run some validation work on general tooling like Jira, as a test-tracking layer for computer system validation. The gap is Part 11: general work-management and test-tracking tools lack electronic signatures out of the box, so a validation team on general tools still has to buy or build a signature integration and a traceability layer to close that piece. No company has published a self-built replacement for the full lifecycle core: risk assessment through signed execution through audit-ready summary. Extend a general tool only if your teams already work there, the scope stays manageable, and you own the signature integration and its own ongoing validation.
When buying makes sense
Buy a validation lifecycle platform when the program spans sites and systems and needs repeatable electronic execution with Part 11 signatures built in from the start. Kneat's deployment at Merck Sharp & Dohme (MSD) digitized seven validation processes across twenty-seven sites, reported a 50% cycle-time cut with 46% fewer process steps, and consolidated the systems in use from five to two. Platforms like ValGenesis and Veeva Vault Validation Management package the recurring work, from risk assessment through scripting, execution and signed summary reports, into a controlled system validation teams use end to end without building the signature and traceability layer themselves. FDA's Part 11 and CSA guidance is risk-based and names no approved platform, so treat a vendor's validation package as an input to your own risk-based assurance rather than as the regulator's acceptance. That assurance work stays yours regardless of which system you choose.
The desk read
Build-versus-buy analysis for Digital Validation for Life Sciences is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.
Frequently asked
Can general work-management tools actually satisfy FDA validation requirements?
Partially. Regulated teams do run test tracking on general tools, but those tools lack Part 11 electronic signatures natively. You still need a signature integration layered on top, and that integration itself needs validating.
What does a dedicated platform like Kneat or ValGenesis actually save?
Kneat's deployment at MSD reported a 50% cycle-time cut across seven digitized processes spanning twenty-seven sites, with 46% fewer process steps and systems consolidated from five to two. The platform absorbs the recurring engineering of signature integration, traceability and audit-ready reporting that a general-tool build has to construct and validate separately.
Does FDA's CSA guidance change whether we should build or buy?
Not directly. CSA shifts assurance effort toward risk-based testing rather than exhaustive scripted testing, but it names no approved platform and does not make any tool compliant by itself. The assurance burden stays with your team either way.
Is validation software itself a source of competitive advantage?
No. Every regulated company follows the same GAMP 5 lifecycle and FDA guidance, so a clean validation record is table stakes that gates product release, not something that wins a customer over a competitor.